Abivax (ABVX), a clinical-stage biotechnology company, requested a temporary halt of trading in its ordinary shares on Euronext Paris from 9:00 a.m. CEST on July 1, 2026. The halt supports confirming allocations and announcing pricing for a previously announced ADS public offering in the United States. Trading is expected to resume around 3:30 p.m. CEST the same day.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – ABVX
-0.53%
49 alerts
-0.53%Session close to close
+5.6%Peak in 31 hr 29 min
$11.62BMarket Cap
0.8xRel. Volume
In the Jul 1 session, ABVX declined 0.53%, reflecting a mild negative market reaction.
Argus tracked a peak move of +5.6% during that session.
Our momentum scanner triggered 49 alerts that day, indicating elevated trading interest and price volatility.
This announcement highlights a temporary Euronext Paris trading halt tied to U.S. ADS offering prici...
Analysis
This announcement highlights a temporary Euronext Paris trading halt tied to U.S. ADS offering pricing and allocations. Investors may compare it to prior financing events, while dilution perceptions and execution of the offering remain key watchpoints.
Key Figures
Announcement time:07:30 a.m. CESTMarket halt start:9:00 a.m. CESTExpected resume time:3:30 p.m. CEST+2 more
5 metrics
Announcement time07:30 a.m. CESTPress release timestamp on July 1, 2026
Market halt start9:00 a.m. CESTOpening time when Euronext Paris trading halt begins
Expected resume time3:30 p.m. CESTExpected time trading on Euronext Paris will resume
Nominal value per share€0.01Nominal value of each ordinary share represented by an ADS in the offering
Ordinary share nominal currency€Shares referenced as euro-denominated ordinary shares on Euronext Paris
Multiple obefazimod abstracts and presentations planned at a major GI conference.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
ABVX usually trades broadly in line with news, but the large selloff on strong Phase 3 results stands out as a notable divergence.
Key Terms
trading halt, regulated market, american depositary shares, pricing of the offering
4 terms
trading haltregulatory
"announced today that trading of its ordinary shares on the regulated market of Euronext Paris (“Euronext Paris”) will be temporarily halted"
A trading halt is a temporary pause on buying and selling a particular stock imposed by an exchange or regulator, like pressing the pause button on a game so everyone can catch up. It is used to give the market time to absorb important new information or to prevent chaotic price swings, and matters to investors because it freezes the ability to trade, delays price discovery, and can change risk and strategy until normal trading resumes.
"trading of its ordinary shares on the regulated market of Euronext Paris (“Euronext Paris”)"
A regulated market is an organized trading venue overseen by government or independent authorities that enforces rules on who can list, what information must be published, and how trades are executed. Think of it like a store that must pass safety inspections and display clear labels: the oversight promotes honesty, regular reporting, and fair access, which helps investors compare options, find buyers and sellers, and reduces the risk of fraud or hidden problems.
american depositary sharesfinancial
"previously announced public offering by the Company of its American Depositary Shares, each representing one ordinary share"
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.
pricing of the offeringfinancial
"allow for the confirmation of allocations to investors and the announcement of the pricing of the Offering"
The pricing of the offering is the decision that sets the price at which new shares or securities will be sold to investors in a public or private sale. It determines how much money the company raises, how many existing owners are diluted, and what valuation the market assigns—similar to choosing the ticket price for a concert, which affects both attendance and total revenue. Investors care because the price influences potential returns, risk, and short-term trading behavior.
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
PARIS, France, July 1, 2026 – 07:30 a.m. CEST –Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announced today that trading of its ordinary shares on the regulated market of Euronext Paris (“Euronext Paris”) will be temporarily halted, at the Company’s request, from the opening of the market at 9:00 a.m. CEST. This trading halt takes place in the context of the previously announced public offering by the Company of its American Depositary Shares, each representing one ordinary share, €0.01 nominal value per share, of the Company, in the United States (the “Offering”), in order to allow for the confirmation of allocations to investors and the announcement of the pricing of the Offering.
This suspension will be effective until a new communication is released by the Company. Trading on Euronext Paris is expected to resume today, July 1, 2026, at approximately 3:30 p.m. (CEST).
***
About Abivax
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of the Company, nor shall there be any sale of such securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Why were Abivax (ABVX) shares temporarily halted on Euronext Paris on July 1, 2026?
Abivax requested a temporary trading halt to support its American Depositary Shares public offering. According to Abivax, the pause allows time to confirm investor allocations and announce the final pricing of the ADS offering in the United States.
When did the Abivax (ABVX) trading halt on Euronext Paris start and when is it expected to end?
The trading halt began at 9:00 a.m. CEST on July 1, 2026. According to Abivax, trading on Euronext Paris is expected to resume the same day, at approximately 3:30 p.m. CEST, after the ADS offering pricing communication.
How is the Abivax (ABVX) ADS public offering related to the Euronext Paris trading halt?
The trading halt is directly linked to Abivax’s American Depositary Shares public offering in the United States. According to Abivax, the pause facilitates confirming allocations to investors and publicly announcing the pricing of the ADS, each representing one ordinary share.
What does the temporary Abivax (ABVX) trading halt mean for current Euronext Paris shareholders?
During the halt, Abivax ordinary shares cannot be traded on Euronext Paris. According to Abivax, the suspension is temporary and is expected to end around 3:30 p.m. CEST on July 1, 2026, once ADS allocation and pricing are communicated.
How long will Abivax (ABVX) shares remain suspended from trading on Euronext Paris?
The suspension is intended to last only part of the trading day on July 1, 2026. According to Abivax, the halt begins at 9:00 a.m. CEST and trading is expected to resume at approximately 3:30 p.m. CEST after the ADS offering pricing announcement.
